Taysha Gene Therapies granted an employee stock options, showcasing commitment to innovation and patient outcomes.

From GlobeNewswire: 2024-09-06 08:00:00

Taysha Gene Therapies, Inc. granted a new employee an option to purchase 311,000 shares of common stock at an exercise price of $2.06 per share on September 3, 2024. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting after one year, and the rest vesting monthly over the following 36 months, contingent on continued service to Taysha. Taysha Gene Therapies is focused on developing gene therapies for severe monogenic CNS diseases, with its lead program TSHA-102 targeting Rett syndrome. For more information, visit their website at www.tayshagtx.com.

Overall, this news highlights Taysha Gene Therapies’ dedication to advancing gene therapies for severe monogenic CNS diseases. The granting of stock options to a new employee demonstrates the company’s commitment to attracting top talent in order to drive innovation and ultimately improve patient outcomes. With a focus on developing transformative medicines, Taysha is positioned to address significant unmet medical needs and make a positive impact on the lives of patients and caregivers.



Read more at GlobeNewswire: Taysha Gene Therapies Announces Inducement Grant Under